Cargando…
COVID-19 infections post-vaccination by HIV status in the United States
IMPORTANCE: Recommendations for additional doses of COVID vaccine are restricted to people with HIV who have advanced disease or unsuppressed HIV viral load. Understanding SARS-CoV-2 infection risk post-vaccination among PWH is essential for informing vaccination guidelines. OBJECTIVE: Estimate the...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669858/ https://www.ncbi.nlm.nih.gov/pubmed/34909791 http://dx.doi.org/10.1101/2021.12.02.21267182 |
_version_ | 1784614863434153984 |
---|---|
author | Coburn, Sally B. Humes, Elizabeth Lang, Raynell Stewart, Cameron Hogan, Brenna C Gebo, Kelly A. Napravnik, Sonia Edwards, Jessie K. Browne, Lindsay E. Park, Lesley S. Justice, Amy C. Gordon, Kirsha Horberg, Michael A. Certa, Julia M. Watson, Eric Jefferson, Celeena R Silverberg, Michael Skarbinski, Jacek Leyden, Wendy A Williams, Carolyn F. Althoff, Keri N. |
author_facet | Coburn, Sally B. Humes, Elizabeth Lang, Raynell Stewart, Cameron Hogan, Brenna C Gebo, Kelly A. Napravnik, Sonia Edwards, Jessie K. Browne, Lindsay E. Park, Lesley S. Justice, Amy C. Gordon, Kirsha Horberg, Michael A. Certa, Julia M. Watson, Eric Jefferson, Celeena R Silverberg, Michael Skarbinski, Jacek Leyden, Wendy A Williams, Carolyn F. Althoff, Keri N. |
author_sort | Coburn, Sally B. |
collection | PubMed |
description | IMPORTANCE: Recommendations for additional doses of COVID vaccine are restricted to people with HIV who have advanced disease or unsuppressed HIV viral load. Understanding SARS-CoV-2 infection risk post-vaccination among PWH is essential for informing vaccination guidelines. OBJECTIVE: Estimate the risk of breakthrough infections among fully vaccinated people with (PWH) and without (PWoH) HIV in the US. DESIGN, SETTING, AND PARTICIPANTS: The Corona-Infectious-Virus Epidemiology Team (CIVET)-II cohort collaboration consists of 4 longitudinal cohorts from integrated health systems and academic health centers. Each cohort identified individuals ≥18 years old, in-care, and fully vaccinated for COVID-19 through 30 June 2021. PWH were matched to PWoH on date fully vaccinated, age group, race/ethnicity, and sex at birth. Incidence rates per 1,000 person-years and cumulative incidence of breakthrough infections with 95% confidence intervals ([,]) were estimated by HIV status. Cox proportional hazards models estimated adjusted hazard ratios (aHR) of breakthrough infections by HIV status adjusting for demographic factors, prior COVID-19 illness, vaccine type (BNT162b2, [Pfizer], mRNA-1273 [Moderna], Jansen Ad26.COV2.S [J&J]), calendar time, and cohort. Risk factors for breakthroughs among PWH, were also investigated. EXPOSURE: HIV infection OUTCOME: COVID-19 breakthrough infections, defined as laboratory evidence of SARS-CoV-2 infection or COVID-19 diagnosis after an individual was fully vaccinated. RESULTS: Among 109,599 individuals (31,840 PWH and 77,759 PWoH), the rate of breakthrough infections was higher in PWH versus PWoH: 44 [41, 48] vs. 31 [29, 33] per 1,000 person-years. Cumulative incidence at 210 days after date fully vaccinated was low, albeit higher in PWH versus PWoH overall (2.8% versus 2.1%, log-rank p<0.001, risk difference=0.7% [0.4%, 1.0%]) and within each vaccine type. Breakthrough infection risk was 41% higher in PWH versus PWoH (aHR=1.41 [1.28, 1.56]). Among PWH, younger age (18–24 versus 45–54), history of COVID-19 prior to fully vaccinated date, and J&J vaccination (versus Pfizer) were associated with increased risk of breakthroughs. There was no association of breakthrough with HIV viral load suppression or CD4 count among PWH. CONCLUSIONS AND RELEVANCE: COVID-19 vaccination is effective against infection with SARS-CoV-2 strains circulating through 30 Sept 2021. PWH have an increased risk of breakthrough infections compared to PWoH. Recommendations for additional vaccine doses should be expanded to all PWH. |
format | Online Article Text |
id | pubmed-8669858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-86698582021-12-15 COVID-19 infections post-vaccination by HIV status in the United States Coburn, Sally B. Humes, Elizabeth Lang, Raynell Stewart, Cameron Hogan, Brenna C Gebo, Kelly A. Napravnik, Sonia Edwards, Jessie K. Browne, Lindsay E. Park, Lesley S. Justice, Amy C. Gordon, Kirsha Horberg, Michael A. Certa, Julia M. Watson, Eric Jefferson, Celeena R Silverberg, Michael Skarbinski, Jacek Leyden, Wendy A Williams, Carolyn F. Althoff, Keri N. medRxiv Article IMPORTANCE: Recommendations for additional doses of COVID vaccine are restricted to people with HIV who have advanced disease or unsuppressed HIV viral load. Understanding SARS-CoV-2 infection risk post-vaccination among PWH is essential for informing vaccination guidelines. OBJECTIVE: Estimate the risk of breakthrough infections among fully vaccinated people with (PWH) and without (PWoH) HIV in the US. DESIGN, SETTING, AND PARTICIPANTS: The Corona-Infectious-Virus Epidemiology Team (CIVET)-II cohort collaboration consists of 4 longitudinal cohorts from integrated health systems and academic health centers. Each cohort identified individuals ≥18 years old, in-care, and fully vaccinated for COVID-19 through 30 June 2021. PWH were matched to PWoH on date fully vaccinated, age group, race/ethnicity, and sex at birth. Incidence rates per 1,000 person-years and cumulative incidence of breakthrough infections with 95% confidence intervals ([,]) were estimated by HIV status. Cox proportional hazards models estimated adjusted hazard ratios (aHR) of breakthrough infections by HIV status adjusting for demographic factors, prior COVID-19 illness, vaccine type (BNT162b2, [Pfizer], mRNA-1273 [Moderna], Jansen Ad26.COV2.S [J&J]), calendar time, and cohort. Risk factors for breakthroughs among PWH, were also investigated. EXPOSURE: HIV infection OUTCOME: COVID-19 breakthrough infections, defined as laboratory evidence of SARS-CoV-2 infection or COVID-19 diagnosis after an individual was fully vaccinated. RESULTS: Among 109,599 individuals (31,840 PWH and 77,759 PWoH), the rate of breakthrough infections was higher in PWH versus PWoH: 44 [41, 48] vs. 31 [29, 33] per 1,000 person-years. Cumulative incidence at 210 days after date fully vaccinated was low, albeit higher in PWH versus PWoH overall (2.8% versus 2.1%, log-rank p<0.001, risk difference=0.7% [0.4%, 1.0%]) and within each vaccine type. Breakthrough infection risk was 41% higher in PWH versus PWoH (aHR=1.41 [1.28, 1.56]). Among PWH, younger age (18–24 versus 45–54), history of COVID-19 prior to fully vaccinated date, and J&J vaccination (versus Pfizer) were associated with increased risk of breakthroughs. There was no association of breakthrough with HIV viral load suppression or CD4 count among PWH. CONCLUSIONS AND RELEVANCE: COVID-19 vaccination is effective against infection with SARS-CoV-2 strains circulating through 30 Sept 2021. PWH have an increased risk of breakthrough infections compared to PWoH. Recommendations for additional vaccine doses should be expanded to all PWH. Cold Spring Harbor Laboratory 2021-12-05 /pmc/articles/PMC8669858/ /pubmed/34909791 http://dx.doi.org/10.1101/2021.12.02.21267182 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Coburn, Sally B. Humes, Elizabeth Lang, Raynell Stewart, Cameron Hogan, Brenna C Gebo, Kelly A. Napravnik, Sonia Edwards, Jessie K. Browne, Lindsay E. Park, Lesley S. Justice, Amy C. Gordon, Kirsha Horberg, Michael A. Certa, Julia M. Watson, Eric Jefferson, Celeena R Silverberg, Michael Skarbinski, Jacek Leyden, Wendy A Williams, Carolyn F. Althoff, Keri N. COVID-19 infections post-vaccination by HIV status in the United States |
title | COVID-19 infections post-vaccination by HIV status in the United States |
title_full | COVID-19 infections post-vaccination by HIV status in the United States |
title_fullStr | COVID-19 infections post-vaccination by HIV status in the United States |
title_full_unstemmed | COVID-19 infections post-vaccination by HIV status in the United States |
title_short | COVID-19 infections post-vaccination by HIV status in the United States |
title_sort | covid-19 infections post-vaccination by hiv status in the united states |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669858/ https://www.ncbi.nlm.nih.gov/pubmed/34909791 http://dx.doi.org/10.1101/2021.12.02.21267182 |
work_keys_str_mv | AT coburnsallyb covid19infectionspostvaccinationbyhivstatusintheunitedstates AT humeselizabeth covid19infectionspostvaccinationbyhivstatusintheunitedstates AT langraynell covid19infectionspostvaccinationbyhivstatusintheunitedstates AT stewartcameron covid19infectionspostvaccinationbyhivstatusintheunitedstates AT hoganbrennac covid19infectionspostvaccinationbyhivstatusintheunitedstates AT gebokellya covid19infectionspostvaccinationbyhivstatusintheunitedstates AT napravniksonia covid19infectionspostvaccinationbyhivstatusintheunitedstates AT edwardsjessiek covid19infectionspostvaccinationbyhivstatusintheunitedstates AT brownelindsaye covid19infectionspostvaccinationbyhivstatusintheunitedstates AT parklesleys covid19infectionspostvaccinationbyhivstatusintheunitedstates AT justiceamyc covid19infectionspostvaccinationbyhivstatusintheunitedstates AT gordonkirsha covid19infectionspostvaccinationbyhivstatusintheunitedstates AT horbergmichaela covid19infectionspostvaccinationbyhivstatusintheunitedstates AT certajuliam covid19infectionspostvaccinationbyhivstatusintheunitedstates AT watsoneric covid19infectionspostvaccinationbyhivstatusintheunitedstates AT jeffersonceleenar covid19infectionspostvaccinationbyhivstatusintheunitedstates AT silverbergmichael covid19infectionspostvaccinationbyhivstatusintheunitedstates AT skarbinskijacek covid19infectionspostvaccinationbyhivstatusintheunitedstates AT leydenwendya covid19infectionspostvaccinationbyhivstatusintheunitedstates AT williamscarolynf covid19infectionspostvaccinationbyhivstatusintheunitedstates AT althoffkerin covid19infectionspostvaccinationbyhivstatusintheunitedstates AT covid19infectionspostvaccinationbyhivstatusintheunitedstates |